relatlimab,nivolumab
bms
['lung', 'neopredict']
neopredict-lung : exploring the feasibility &amp; efficacy of targeting pd-1 and lag-3 prior to resection --&gt; r0 resection rate was 97%. complete or major histopathological response 30% in the combination arm #esmo2022 
Assistant Prof | Thoracic Oncology & Phase-I  @karmanoscancer | Previously @MayoCancerCare @gundersenhealth @JeffHealthAb @bpkihsofficial | Views/Tweets my own